Seoul Pharma
Daily close in US$ at the latest USD/KRW close. Source: KRX via FinanceDataReader.
Seoul Pharma makes prescription medicines, including digestive and acid-relief tablets, supplied to patients through the South Korean healthcare system.
It is listed on KOSDAQ, Korea's tech and small-cap exchange. The company is actively developing improved-formulation drugs, with a particular focus on a proprietary oral dissolving film technology it calls SmartFilm®, and has completed construction of a new facility built to internationally recognised current Good Manufacturing Practice standards to support entry into advanced markets.
Summary is AI-generated and may contain errors · figures from DART filings
Seoul Pharma has completed a new cGMP-standard manufacturing facility in Osong, South Korea, aimed at enabling entry into the US and other advanced pharmaceutical markets.
Seoul Pharma in five facts
What does Seoul Pharma do?
Seoul Pharma makes prescription medicines, including digestive and acid-relief tablets, supplied to patients through the South Korean healthcare system.
Where is Seoul Pharma listed and in which sector?
Seoul Pharma (Korean name: 서울제약) trades under KRX code 018680 on KOSDAQ, the Korea Exchange's board for smaller and growth companies. It is classified in the Health Care sector, Pharmaceuticals.
How large is Seoul Pharma?
Its market capitalisation was US$16.7M on 2026-10-21, which puts it in this site's small-cap group. US$ amounts are converted from won at 1 USD ≈ ₩1,325 (2026-10-21).
What were Seoul Pharma's latest annual revenue and operating profit?
For fiscal year 2025, Seoul Pharma reported revenue of US$39.4M, an operating loss of US$965.6K and net income of US$568.8K, per its annual report on DART (data retrieved from DART on 2026-09-08). Revenue was down 2.7% on the previous year.
Where does this data come from?
Financial statements and filings come from DART, Korea's official corporate-filing system. Share prices, market capitalisation and trading status come from KRX. Company summaries are AI-generated from the filings and may contain errors; financial figures are mapped directly from DART.
Data sources and last updated
- Filings and financial statements
- DART (dart.fss.or.kr), Korea's official corporate-filing system
- Prices, market cap, trading status
- KRX (Korea Exchange), via FinanceDataReader
- Latest annual financials
- Fiscal year 2025, data retrieved from DART on 2026-09-08
- Share price and market cap
- Close of 2026-10-21
- Currency
- US$, converted from won at 1 USD ≈ ₩1,325 (2026-10-21 close)
- Company data updated
- 2026-10-21
- Company summary
- AI-generated from filings; may contain errors. Information only, not investment advice.